Experts Discuss Pros and Cons of Maintenance of Certification

Share this content:
Experts Discuss Pros and Cons of Maintenance of Certification
Experts Discuss Pros and Cons of Maintenance of Certification

(HealthDay News) -- The pros and cons of the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) are discussed in two articles published in the Jan. 8 issue of the New England Journal of Medicine.

Mira B. Irons, M.D., and Lois M. Nora, M.D., J.D., from the American Board of Medical Specialties in Chicago, discuss the controversy surrounding the MOC. To address the exponential increases in knowledge and research, the U.S. medical specialty boards adopted the MOC as part of an integrated quality-improvement framework. The researchers note that there is growing evidence that MOC can improve physician performance and patient outcomes. To ensure the program meets the needs of patients, physicians, and the greater community, periodic reevaluation is necessary. The 2015 MOC provides an opportunity to work toward improving patient care and support physicians.

Paul S. Teirstein, M.D., from Scripps Clinic and the Scripps Prebys Cardiovascular Institute in La Jolla, Calif., describes other aspects of MOC. He notes that evidence supporting the value of MOC is ambiguous at best. Furthermore, the rigorous requirements for initial certification cannot be equated with the requirement for MOC every two years. Lifelong learning alternatives exist in the form of continuing medical education, which physicians have accepted as having value. Many physicians are opposed to MOC and its new requirements. An alternative certification option offered to compete with ABIM would benefit patients and physicians.

"Many physicians are waking up to the fact that our profession is increasingly controlled by people not directly involved in patient care who have lost contact with the realities of day-to-day clinical practice," Teirstein writes.

Full Text - Irons and Nora
Full Text - Teirstein

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths